Business Wire

bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype

Share

bluebird bio, Inc . (Nasdaq: BLUE) announced today that the European Commission (EC) has granted conditional marketing authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene), a gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β00 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. bluebird bio will continue the country-by-country reimbursement process to help ensure access to ZYNTEGLO for appropriate patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190603005497/en/

TDT is a severe genetic disease caused by mutations in the β-globin gene that result in reduced or absent hemoglobin. In order to survive, people with TDT maintain hemoglobin levels through lifelong chronic blood transfusions. These transfusions carry the risk of progressive multi-organ damage due to unavoidable iron overload. ZYNTEGLO is a one-time gene therapy that addresses the underlying genetic cause of TDT and offers patients 12 years and older who do not have a β00 genotype the potential to become transfusion independent, which once achieved is expected to be life-long.

“EC approval of ZYNTEGLO is a milestone that represents the dedication and commitment of clinical investigators, healthcare providers, patients and their families, and our employees, all of whom have helped advance this treatment from concept to an approved therapy,” said Nick Leschly, chief bluebird. “Our first product approval is a humbling moment for all of us at bluebird, and we look forward to continuing our work with the TDT community and health systems to bring this important treatment to patients.”

ZYNTEGLO was reviewed as part of the European Medicines Agency’s (EMA) Priority Medicines (PRIME) and Adaptive Pathways programs, which support medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options. The PRIME and Adaptive Pathway programs allowed for early and enhanced dialogue and accelerated assessment of ZYNTEGLO, which was completed on the shortest timetable for an advanced therapy medicinal product (ATMP) by the EMA to date.

“As one of the investigators in the clinical studies of ZYNTEGLO, I have witnessed firsthand the hope this gene therapy can provide to patients and their families who have often been managing this disease and transfusions for years, often for decades,” said Professor Franco Locatelli, M.D., Ph.D., Professor of Pediatrics, Sapienza University of Rome, Italy, and Director, Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy. “This approval by the European Commission means we now have a gene therapy for certain patients with TDT that has the potential to transform lives by offering the possibility of a transfusion-free future.”

ZYNTEGLO adds functional copies of a modified form of the β-globin gene (βA-T87Q-globin gene) into a patient’s own hematopoietic (blood) stem cells (HSCs). This means there is no need for donor HSCs from another person as is required for allogeneic HSC transplantation (allo-HSCT). A patient’s HSCs are removed from the body through a process called apheresis. These HSCs are taken to a lab where a lentiviral vector is used to insert the βA-T87Q-globin gene into the patient’s HSCs. This step is called transduction. Before their modified HSCs are returned through infusion, a patient receives chemotherapy to prepare their bone marrow for the modified HSCs that now carry the βA-T87Q-globin gene. Once a patient has the βA-T87Q-globin gene they have the potential to produce HbAT87Q, which is gene therapy-derived-hemoglobin, at levels that eliminate or significantly reduce the need for transfusions. Upon engraftment and achievement of transfusion independence, effects of ZYNTEGLO are expected to be life-long.

Due to the highly technical and specialized nature of administering gene therapy in rare diseases, bluebird bio is working with select qualified treatment centers that have expertise in stem cell transplant and treating patients with TDT to provide ZYNTEGLO.

“We welcome European Commission authorization for the first gene therapy for TDT. This achievement means the TDT community now has another treatment option that may provide new hope for people living with TDT who have been managing their disease through chronic transfusions,” said Dr. Androulla Eleftheriou, Thalassemia International Federation Executive Director. “Undoubtedly, this is not the end of the road, but merely the beginning, and TIF is ready to collaborate with all involved stakeholders to help ensure accessibility for as many appropriate patients as possible.”

The conditional marketing authorization is valid in all 28 member states of the EU as well as Iceland, Liechtenstein and Norway.

Data Supporting Clinical Profile of ZYNTEGLO

The conditional marketing authorization is supported by efficacy, safety and durability data from the Phase 1/2 HGB-205 study and the completed Phase 1/2 Northstar (HGB-204) study as well as available data from the ongoing Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies, and the long-term follow-up study LTF-303, as of the data cut off of December 13, 2018.

Data from Phase 1/2 HGB-205 showed that 75 percent (n=3/4) of patients who do not have a β00 genotype achieved transfusion independence, meaning they had not received a transfusion for at least 12 months or more and maintained weighted hemoglobin ≥9 g/dL. In the Phase 1/2 Northstar study, 80 percent (n=8/10) of patients who do not have a β00 genotype achieved transfusion independence.

These 11 patients (three from HGB-205 and eight from Northstar) continued to maintain transfusion independence, which at the time of data cut off was for a duration of 21–56 months.

Five patients in Northstar-2 were evaluable for transfusion independence. Of these five, 80 percent (n=4/5) achieved transfusion independence.

Non-serious adverse events (AEs) observed during clinical trials that were attributed to ZYNTEGLO were hot flush, dyspnoea, abdominal pain, pain in extremities and non-cardiac chest pain. One serious adverse event (SAE) of thrombocytopenia was considered possibly related to ZYNTEGLO.

Additional AEs observed in clinical studies were consistent with the known side effects of HSC collection and bone marrow ablation with busulfan, including SAEs of veno-occlusive disease.

For details, please see the Summary of Product Characteristics (SmPC).

ZYNTEGLO continues to be evaluated in the ongoing Phase 3 Northstar-2 and Northstar-3 studies and the long-term follow-up study LTF-303.

In addition to Priority Medicines (PRIME) designation, ZYNTEGLO received an Orphan Medicinal Product designation from the EC for the treatment of β-thalassemia intermedia and major, which includes TDT.

The U.S. Food and Drug Administration granted ZYNTEGLO Orphan Drug status and Breakthrough Therapy designation for the treatment of TDT.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbioLinkedInInstagram and YouTube.

ZYNTEGLO and LentiGlobin are trademarks of bluebird bio.

The full common name for ZYNTEGLO: A genetically modified autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiviral vector encoding the βA-T87Q-globin gene.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plans and expectations for the commercialization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene, formerly LentiGlobin™ in TDT) to treat TDT, and the potential implications of clinical data for patients. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the efficacy and safety results from our prior and ongoing clinical trials of ZYNTEGLO will not continue or be repeated in our ongoing or planned clinical trials of ZYNTEGLO; the risk that the current or planned clinical trials of ZYNTEGLO will be insufficient to support regulatory submissions or marketing approval in the US, or for additional patient populations in the EU; the risk that the production of HbAT87Q may not be sustained over extended periods of time; and the risk that we may not secure adequate pricing or reimbursement to support continued development or commercialization of ZYNTEGLO following regulatory approval. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

Contact information

bluebird bio
Investors:
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com
or
Media:
Catherine Falcetti, 339-499-9436
cfalcetti@bluebirdbio.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acrisure and Tulco Unveil Altway Insurance19.9.2019 16:00:00 CESTPress release

Top 10 global insurance broker Acrisure and leading investment company Tulco Holdings unveils Altway Insurance, a direct-to-consumer brokerage platform which is fully supported by artificial intelligence. Altway Insurance represents a unique blend of a world-class AI firm matched with an insurance broker with an equally world-class distribution network. Additionally, Google Cloud is working closely with the company on how to integrate Google's most cutting-edge AI technology into new AI applications. Tulco Chairman and CEO Thomas Tull said, “While there has been substantial investment to fuse technology and insurance, today, there remains a massive and unmet opportunity to truly create the broker of the future. To meet that opportunity, we're thrilled to combine the AI and analytics leadership of Tulco with the phenomenal growth and global distribution power of Acrisure.” Underlying Altway is the unique combination of Acrisure and Tulco. Acrisure delivers high quality insurance service

Mindbreeze recognized once again as a Leader in the 2019 Gartner Magic Quadrant for Insight Engines19.9.2019 15:20:00 CESTPress release

Mindbreeze, a leading global provider of appliances and cloud services for information insight and applied artificial intelligence with a focus on knowledge management for international companies, announced today that the company has been positioned by Gartner, Inc. as a Leader in the 2019 Magic Quadrant for Insight Engines. A complimentary copy of the report can be accessed from the Mindbreeze website “Mindbreeze enables our customers and their employees to garner and leverage crucial insights from their data. We work directly with our customers in this innovative field to bring meaning and value to their information assets that take us to the next level together,” comments Daniel Fallmann, Mindbreeze CEO and founder. “We believe this recognition further validates Mindbreeze’s success in the AI and knowledge management industry, as enterprises achieve ideal results using our unique and innovative solution.” Download the 2019 Magic Quadrant for Insight Engines now Many well-known custo

Amazon Co-founds The Climate Pledge, Setting Goal to Meet the Paris Agreement 10 Years Early19.9.2019 15:15:00 CESTPress release

Today, Amazon (NASDAQ: AMZN) and Global Optimism announced The Climate Pledge, a commitment to meet the Paris Agreement 10 years early. Amazon today becomes the first signatory of this pledge. The Climate Pledge calls on signatories to be net zero carbon across their businesses by 2040—a decade ahead of the Paris Accord’s goal of 2050. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190919005609/en/ Companies that sign The Climate Pledge agree to: Measure and report greenhouse gas emissions on a regular basis; Implement decarbonization strategies in line with the Paris Agreement through real business changes and innovations, including efficiency improvements, renewable energy, materials reductions, and other carbon emission elimination strategies; Neutralize any remaining emissions with additional, quantifiable, real, permanent, and socially-beneficial offsets to achieve net zero annual carbon emissions by 2040. “We’re done b

In Impact Investing First, LeapFrog Announces Audit on Impact Principles, Achieving Top Rating19.9.2019 15:02:00 CESTPress release

LeapFrog Investments today became the first impact investor globally to announce the results of an independent audit of its impact against the Operating Principles for Impact Management, new industry standards developed by the IFC in consultation with leading impact investors and other stakeholders. Launched in April, the Principles provide common disciplines for management of investments for impact, helping to ensure authenticity and high standards of measurement. In the independent audit by Tideline, a leading US impact advisory consultancy, LeapFrog was assessed as an “Exemplification of industry best practice,” with its Impact Measurement and Management (IMM) system achieving “an advanced level of alignment across the board for all nine of the Principles.” Tideline concluded that “LeapFrog’s IMM comprehensively addresses and exceeds the implementation guidance provided by the IFC and has been refined and strengthened over the course of several funds.” “The impact investing industry

Andersen Global Expands Reach in London19.9.2019 13:30:00 CESTPress release

Andersen Global continues its expansion in the UK as Miles Dean, Zoe Wyatt and their team join the Andersen Tax LLP team in the UK. This addition brings further depth to the group in London and enhances the team’s ability to work with clients holistically and provide best-in-class, seamless service. Andersen Global has a presence in five locations in the UK through its member and collaborating firms. Miles and Zoe previously worked at Milestone which was founded by Miles Dean in 2008, with Zoe Wyatt joining as a partner in 2015. As part of Andersen Tax LLP, these partners will continue to provide a broad range of international tax services to corporations and private clients, investment funds and real estate investors and developers. Milestone signed a collaboration agreement with Andersen Global in 2018 and the positive impact of this relationship has led to Miles, Zoe and their team now joining the Andersen Global member firm in the UK. “It was so important to us to ensure we are pos

CGLytics and Glass Lewis Set a New Standard for Transparency in Equity-based Compensation19.9.2019 13:15:00 CESTPress release

CGLytics, a leading global provider of governance data and analytics, and Glass Lewis, the world’s leading independent provider of governance and engagement support services, today announced the launch of Glass Lewis’ Equity Compensation Model (ECM) - a powerful new application for assessing U.S. equity-based compensation plans, available exclusively via CGLytics. This new application provides invaluable intelligence with year-round, on-demand access to Glass Lewis’ methodology which is used to evaluate the overall favorability of current and future equity plans, including tests against 11 key criteria. Companies and investors can now instantly test, review and adjust the same individual inputs as Glass Lewis’ analysts to ensure the best compensation, engagement and voting outcomes for their respective sides. The ECM provides companies with immediate and proactive insight into the concerns regarding current and future equity plans, which Glass Lewis highlights to more than 1,300 invest